A Phase 3 Randomized Placebo-controlled Multicenter Study of Upifitamab Rilsodotin (UpRi) as Post-Platinum Maintenance Therapy for Participants with Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT).

Brief description of study

You can participate in this study if you are diagnosed with Platinum-Sensitive Recurrent Ovarian Cancer. In this study we will evaluate the study drug (Upifitamab rilsodotin) as post-platinum maintenance therapy for participants with platinum-sensitive recurrent ovarian Cancer.

Clinical Study Identifier: s21-01204

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.